NCT04504708View on ClinicalTrials.gov

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

July 8, 2022

Study Completion Date

July 8, 2022

Conditions
Non-hodgkin LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

ZX-101A

Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle

Trial Locations (6)

43614

University of Toledo Precision Oncology Research, Toledo

85234

Banner MD Anderson Cancer Center, Gilbert

85715

ACRC/Arizona Clinical Research Center, Inc., Tucson

90804

Innovative Clinical Research Institute, Long Beach

98109

Seattle Cancer Care Alliance, Seattle

08724

New Jersey Center for Cancer Research, Brick

Sponsors
All Listed Sponsors
lead

Hangzhou Zenshine Pharmaceuticals Co., Ltd.

INDUSTRY

NCT04504708 - Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | Biotech Hunter | Biotech Hunter